The Paediatric Team
The Leeds paediatric ECMC team is based at Leeds Children’s Hospital, on the Leeds General Infirmary site. We are an established principal treatment centre (PTC) for paediatric oncology and haematology and we have a leading teenage and young adult service for patients age 13 -25 years.
Leeds has a long history of treating children in early phase clinical trials and is a member of the European network of early phase clinical trial centres (ITCC). The paediatric oncology research teams are embedded within the Leeds Children’s Hospital Clinical Research Team, promoting shared knowledge and best practice and ensuring clinical research care is delivered to a high quality by staff with appropriate skills. The team also works collaboratively with the adult oncology research teams, particularly for any trials which recruit patients across the age ranges.
The paediatric ECMC team has a close working relationship with other principal treatment centres in Northern England and the paediatric ECMC centres in Manchester and Liverpool and is supported by the relevant NIHR clinical research networks to facilitate access of early phase clinical trials to all patients in the north across the three ECMC centres.
There are eight consultants some of whom lead national or European clinical trials, three of whom are University of Leeds and University of York academics. The department has close links with basic science and translational research teams in University of Leeds (Candlelighter’s laboratory, Brain Tumour laboratory) and the Epidemiology and Health Services Research Group.
Martin is a paediatric oncologist at Leeds Children's Hospital who treats children and teenagers with a range of tumours including brain tumours. His areas of interest are neuroblastoma, early phase clinical trials and brain tumours.
Martin is the UK lead for the current European high risk neuroblastoma clinical trial in the UK, and he manages the portfolio of early phase clincal trials for paediatric oncology patients in Leeds. These trials are mainly for patients with relapsed tumours where standard treatments have failed and patients and parents are wanting to try more experimental treatments.
He is one of the paediatric oncologists who specialises in the treatment of children and teenagers with brain tumours.
Leeds Paediatric ECMC has wide experience of first-in-man and proof-of-principle early clinical trials of small molecules and biotherapies, both as single agents and in combination.
